Chinese biotech firms are now grabbing the lion’s share of the world’s upfront drug‑deal payments. In September, 74% of all upfront cash in global pharma transactions went to Chinese innovative medicines, showing that multinational giants are betting heavily on China’s pipeline. Two headline deals illustrate the trend. Hengrui Medicine licensed its dual‑target GLP‑1R/GIPR candidate HRS‑1596 to Novo Nordisk in a deal worth up to $2.6 billion, with a $300 million upfront payment. Meanwhile, Merck snapped up Sirta’s KRAS G12D program for $2.13 billion, front‑loading $400 million – the biggest upfront sum recorded this month. The excitement isn’t limited to cash. The Sci‑Tech Innovative Drug ETF (Huatianfu, 589120) has drawn more than 100 million RMB each day for four straight days, reflecting investor enthusiasm for China’s drug innovators. Adding to the buzz, the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid (Oct 23‑27) will showcase over 90 late‑breaking abstracts, with 12 slated for plenary presentation. Chinese projects ranging from bispecific antibodies and antibody‑drug conjugates to novel molecular glues are among the highlights, offering a glimpse of the clinical value and global competitiveness of domestic breakthroughs. This wave of funding and scientific spotlight signals a new era of Chinese drugs moving from lab benches to worldwide markets.
Read moreA new eye‑care drug called Nanoscope MCO‑010 is generating excitement after its latest Phase 3 study, known as RESTORE 2b, delivered striking results. In the trial, roughly 40 percent of participants experienced a jump of at least three lines on a standard eye chart—a gain measured as 0.3 logMAR that can mean the difference between reading a newspaper and needing glasses. The study is part of a broader push, with 16 human clinical trials now running worldwide to test the technology’s potential across a range of conditions. While the eye‑focused trial is the most advanced, researchers are also exploring MCO‑010 for neurological disorders such as Parkinson’s disease, epilepsy, and depression, hoping the same nanoscopic delivery system could protect or restore brain function. If the drug continues to perform, it could become one of the first Chinese‑origin therapies to achieve global regulatory approval, giving Chinese biotech firms a confidence boost and signaling that home‑grown innovation can compete on the world stage. The next steps include larger safety studies and discussions with health authorities about fast‑track approval pathways, bringing the prospect of a new, non‑surgical vision‑restoring option closer to patients.
Read more